Go to
JCI Insight
Citations to this article
Anjui Wu, … , Stefano Lise, Gerhardt Attard
Published March 9, 2020
Citation Information: J Clin Invest. 2020;130(4):1991-2000. https://doi.org/10.1172/JCI130887.
Citation Information: J Clin Invest. 2020;130(4):1991-2000. https://doi.org/10.1172/JCI130887.
Abstract
Tumor DNA circulates in the plasma of cancer patients admixed with DNA from noncancerous cells. The genomic landscape of plasma DNA has been characterized in metastatic castration-resistant prostate cancer (mCRPC) but the plasma methylome has not been extensively explored. Here, we performed next-generation sequencing (NGS) on plasma DNA with and without bisulfite treatment from mCRPC patients receiving either abiraterone or enzalutamide in the pre- or post-chemotherapy setting. Principal component analysis on the mCRPC plasma methylome indicated that the main contributor to methylation variance (principal component one, or PC1) was strongly correlated with genomically determined tumor fraction (r = –0.96; P < 10–8) and characterized by hypermethylation of targets of the polycomb repressor complex 2 components. Further deconvolution of the PC1 top-correlated segments revealed that these segments are comprised of methylation patterns specific to either prostate cancer or prostate normal epithelium. To extract information specific to an individual’s cancer, we then focused on an orthogonal methylation signature, which revealed enrichment for androgen receptor binding sequences and hypomethylation of these segments associated with AR copy number gain. Individuals harboring this methylation pattern had a more aggressive clinical course. Plasma methylome analysis can accurately quantitate tumor fraction and identify distinct biologically relevant mCRPC phenotypes.
Authors
Anjui Wu, Paolo Cremaschi, Daniel Wetterskog, Vincenza Conteduca, Gian Marco Franceschini, Dimitrios Kleftogiannis, Anuradha Jayaram, Shahneen Sandhu, Stephen Q. Wong, Matteo Benelli, Samanta Salvi, Giorgia Gurioli, Andrew Feber, Mariana Buongermino Pereira, Anna Maria Wingate, Enrique Gonzalez-Billalebeitia, Ugo De Giorgi, Francesca Demichelis, Stefano Lise, Gerhardt Attard
Citation information
Citations to this article (56)
| Title and authors | Publication | Year |
|---|---|---|
|
Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer
Sipola J, Munzur AD, Kwan EM, Seo CC, Hauk BJ, Parekh K, Liao YJ, Bernales CQ, Donnellan G, Bloise I, Fung E, Ng SW, Wang G, Vandekerkhove G, Nykter M, Annala M, Maurice-Dror C, Chi KN, Herberts C, Wyatt AW, Takeda DY |
Cancer research | 2025 |
|
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Sharifi MN, Sperger JM, Taylor AK, Tippins KE, Reese SR, Carreno V, Kaufmann KR, Chang AH, Nunamaker LA, Linebarger C, Mora-Rodriguez L, Schehr JL, Krause HM, Helzer KT, Bootsma ML, Blitzer GC, Floberg JM, Kyriakopoulos CE, Emamekhoo H, Heath EI, Wells M, Tagawa ST, Sjöström M, Choudhury AD, Yu M, Armstrong AJ, Rathkopf DE, Beltran H, Nelson PS, Feng FY, Dehm SM, Kosoff D, Wei XX, McKay RR, Zhao SG, Lang JM |
Cancer Discovery | 2025 |
|
Plasma Cell-Free DNA Methylation-Based Prognosis in Metastatic Castrate-Resistant Prostate Cancer.
Wong J, Tian Y, Patel MS, Avasthi K, Hanson C, Larsen M, Ampaw E, Fadlullah MZH, Finklestein J, Tan AC, Park J, Manley BJ, Huang CC, Kohli M, Wang L |
Research square | 2025 |
|
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer
Conteduca V, Scarpi E, Rossi A, Ferroni F, Gurioli G, Bleve S, Gianni C, Schepisi G, Brighi N, Lolli C, Cursano MC, Virga A, Casadei C, Altavilla A, Farolfi A, Ulivi P, Barone D, Matteucci F, De Giorgi U |
The Oncologist | 2025 |
|
Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes
Brighi N, Schepisi G, Conteduca V, Scarpi E, Caroli P, Matteucci F, Lolli C |
OncoTargets and Therapy | 2025 |
|
The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target.
Zhou X, Chai K, Zhu H, Luo C, Zou X, Zou J, Zhang G |
BMC Cancer | 2024 |
|
A review on trends in development and translation of omics signatures in cancer.
Ma W, Tang W, Kwok JSL, Tong AHY, Lo CWS, Chu ATW, Chung BHY |
Computational and Structural Biotechnology Journal | 2024 |
|
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.
Franceschini GM, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku SY, Sigouros M, Rothmann E, Alonso A, Benelli M, Nardella C, Auh J, Freeman D, Hanratty B, Adil M, Elemento O, Tagawa ST, Feng FY, Caffo O, Buttigliero C, Basso U, Nelson PS, Corey E, Haffner MC, Attard G, Aparicio A, Demichelis F, Beltran H |
Cancer Discovery | 2024 |
|
Circulating, cell-free methylated DNA indicates cellular sources of allograft injury after liver transplant
McNamara ME, Jain SS, Oza K, Muralidaran V, Kiliti AJ, McDeed AP, Patil D, Cui Y, Schmidt MO, Riegel AT, Kroemer AH, Wellstein A |
2024 | |
|
Advances in sequencing and omics studies in prostate cancer: unveiling molecular pathogenesis and clinical applications
Lu B, Liu Y, Yao Y, Yang T, Zhang H, Yang X, Huang R, Zhou W, Pan X, Cui X |
Frontiers in Oncology | 2024 |
|
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer
Perez-Navarro E, Conteduca V, Funes JM, Dominguez JI, Martin-Serrano M, Cremaschi P, Fernandez-Perez MP, Gordoa TA, Font A, Vázquez-Estévez S, González-del-Alba A, Wetterskog D, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez Sanchez A, Santander C, Sáez MI, Puente J, Tudela J, Marinas C, López-Andreo MJ, Castellano D, Attard G, Grande E, Rosino A, Botia JA, Palma-Mendez J, De Giorgi U, Gonzalez-Billalabeitia E |
Cancers | 2024 |
|
Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers
Chrenková E, Študentová H, Holá K, Kahounová Z, Hendrychová R, Souček K, Bouchal J |
Frontiers in Oncology | 2024 |
|
Association of Androgen-Receptor Gene Mutations with the Copy Number of Androgen-Receptor Silk Protein A Complex and Glutathione-S-Transferases T1 and M1 in Prostate Cancer Patients
Zhang Y, Meng X, Ma Z, Sun Z, Wang Z |
Genetics Research | 2023 |
|
DNA-methylation and genomic copy number in primary tumors and corresponding lymph node metastases in prostate cancer from patients with low and high Gleason score
Unger K, Hess J, Link V, Buchner A, Eze C, Li M, Stief C, Kirchner T, Klauschen F, Zitzelsberger H, Niyazi M, Ganswindt U, Schmidt-Hegemann NS, Belka C |
Clinical and Translational Radiation Oncology | 2023 |
|
Cell-free, methylated DNA in blood samples reveals tissue-specific, cellular damage from radiation treatment
Megan E. Barefoot, Netanel Loyfer, Amber J Kiliti, Marcel O. Schmidt, Sapir Shabi-Porat, Sidharth S Jain, Sarah Martinez Roth, Arthur P McDeed, Nesreen Shahrour, Elizabeth Ballew, Yun-Tien Lin, Heng-Hong Li, Anne Deslattes Mays, Sonali Rudra, Anna Riegel, Keith Unger, Tommy Kaplan, Anton Wellstein |
JCI Insight | 2023 |
|
DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations.
Gallon J, Rodriguez-Calero A, Benjak A, Akhoundova D, Maletti S, Amstutz U, Hewer E, Genitsch V, Fleischmann A, Rushing EJ, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya AO, Bubendorf L, Moch H, Thalmann G, Feng FY, Gillessen S, Ng CKY, Rubin MA, Piscuoglio S |
Cancer research | 2023 |
|
Recent advances in understanding DNA methylation of prostate cancer.
Shin HJ, Hua JT, Li H |
Frontiers in Oncology | 2023 |
|
Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers.
Rafikova G, Gilyazova I, Enikeeva K, Pavlov V, Kzhyshkowska J |
International journal of molecular sciences | 2023 |
|
Genome-wide studies in prostate cancer poised liquid biopsy as a molecular discovery tool
Lo N, He HH, Chen S |
Frontiers in Oncology | 2023 |
|
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314
Lu YT, Plets M, Morrison G, Cunha AT, Cen SY, Rhie SK, Siegmund KD, Daneshmand S, Quinn DI, Meeks JJ, Lerner SP, Petrylak DP, McConkey D, Flaig TW, Thompson IM Jr, Goldkorn A |
2023 | |
|
Epigenetic regulation of breast cancer metastasis.
Thakur C, Qiu Y, Pawar A, Chen F |
Cancer metastasis reviews | 2023 |
|
Epigenetic (De)regulation in Prostate Cancer.
Xu C, Zhao S, Cai L |
Cancer treatment and research | 2023 |
|
The role of RNA modification in urological cancers: mechanisms and clinical potential
Zhou X, Zhu H, Luo C, Yan Z, Zheng G, Zou X, zou J, Zhang G |
Discover. Oncology | 2023 |
|
Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer
Yamada Y, Venkadakrishnan VB, Mizuno K, Bakht M, Ku SY, Garcia MM, Beltran H |
Science Translational Medicine | 2023 |
|
A clinical-grade liquid biomarker to detect neuroendocrine differentiation in prostate cancer
Shuang Zhao, Jamie Sperger, Jennifer Schehr, Rana McKay, Hamid Emamekhoo, Anupama Singh, Zachery Schultz, Rory Bade, Charlotte Stahlfeld, Cole Gilsdorf, Camila Hernandez, Serena Wolfe, Richel Mayberry, Matt Bootsma, Kyle Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Christos Kyriakopoulos, David Kosoff, Xiao Wei, John Floberg, Nan Sethakorn, Marina Sharifi, Paul Harari, Wei Huang, Himisha Beltran, Toni Choueiri, Howard Scher, Dana Rathkopf, Susan Halabi, Andrew Armstrong, David Beebe, Menggang Yu, Kaitlin Sundling, Mary-Ellen Taplin, Joshua Lang |
Journal of Clinical Investigation | 2022 |
|
Epigenetic modification regulates tumor progression and metastasis through EMT (Review)
T Tan, P Shi, M Abbas, Y Wang, J Xu, Y Chen, H Cui |
International journal of oncology | 2022 |
|
A Mini-Review of Flavone Isomers Apigenin and Genistein in Prostate Cancer Treatment
X Ji, K Liu, Q Li, Q Shen, F Han, Q Ye, C Zheng |
Frontiers in pharmacology | 2022 |
|
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer
V Tulpule, G Morrison, M Falcone, D Quinn, A Goldkorn |
Current Oncology Reports | 2022 |
|
Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges
B Trujillo, A Wu, D Wetterskog, G Attard |
British Journal of Cancer | 2022 |
|
Functions and mechanisms of N6‑methyladenosine in prostate cancer (Review).
Wan H, Feng Y, Wu J, Zhu L, Mi Y |
Molecular medicine reports | 2022 |
|
Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer
Jang A, Rauterkus GP, Vaishampayan UN, Barata PC |
OncoTargets and therapy | 2022 |
|
Prostate cancer in omics era.
Gholami N, Haghparast A, Alipourfard I, Nazari M |
Cancer Cell International | 2022 |
|
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors.
Chen S, Petricca J, Ye W, Guan J, Zeng Y, Cheng N, Gong L, Shen SY, Hua JT, Crumbaker M, Fraser M, Liu S, Bratman SV, van der Kwast T, Pugh T, Joshua AM, De Carvalho DD, Chi KN, Awadalla P, Ji G, Feng F, Wyatt AW, He HH |
Nature Communications | 2022 |
|
Complexities of Prostate Cancer
Wasim S, Lee SY, Kim J |
International journal of molecular sciences | 2022 |
|
A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
Doebley AL, Ko M, Liao H, Cruikshank AE, Santos K, Kikawa C, Hiatt JB, Patton RD, De Sarkar N, Collier KA, Hoge AC, Chen K, Zimmer A, Weber ZT, Adil M, Reichel JB, Polak P, Adalsteinsson VA, Nelson PS, MacPherson D, Parsons HA, Stover DG, Ha G |
Nature Communications | 2022 |
|
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SW, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY |
Cancer research | 2022 |
|
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
De Sarkar N, Patton RD, Doebley AL, Hanratty B, Adil M, Kreitzman AJ, Sarthy JF, Ko M, Brahma S, Meers MP, Janssens DH, Ang LS, Coleman IM, Bose A, Dumpit RF, Lucas JM, Nunez TA, Nguyen HM, McClure HM, Pritchard CC, Schweizer MT, Morrissey C, Choudhury AD, Baca SC, Berchuck JE, Freedman ML, Ahmad K, Haffner MC, Montgomery RB, Corey E, Henikoff S, Nelson PS, Ha G |
Cancer Discovery | 2022 |
|
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
V Conteduca, A Mosca, N Brighi, U de Giorgi, P Rescigno |
Cells | 2021 |
|
Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer
I Casanova-Salas, A Athie, P Boutros, M Re, D Miyamoto, K Pienta, E Posadas, A Sowalsky, A Stenzl, A Wyatt, J Mateo |
European Urology | 2021 |
|
Detection of Cell Types Contributing to Cancer From Circulating, Cell-Free Methylated DNA
ME Barefoot, N Loyfer, AJ Kiliti, AP McDeed, T Kaplan, A Wellstein |
Frontiers in Genetics | 2021 |
|
Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer
R Silva, B Moran, AM Baird, CJ ORourke, SP Finn, R McDermott, W Watson, WM Gallagher, DJ Brennan, AS Perry |
Clinical Epigenetics | 2021 |
|
Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer
A Kumaraswamy, KR Leng, TC Westbrook, JA Yates, SG Zhao, CP Evans, FY Feng, TM Morgan, JJ Alumkal |
European Urology | 2021 |
|
Bridging the Gaps between Circulating Tumor Cells and DNA Methylation in Prostate Cancer
BC Flores, MP Correia, JG Rodríguez, R Henrique, C Jerónimo |
Cancers | 2021 |
|
Identification of prognosis-related molecular subgroups based on DNA methylation in pancreatic cancer
X Yin, L Kong, P Liu |
Clinical Epigenetics | 2021 |
|
The roles of epigenetics in cancer progression and metastasis
JF Chen, Q Yan |
Biochemical Journal | 2021 |
|
A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer
EB Ylitalo, E Thysell, M Landfors, M Brattsand, E Jernberg, S Crnalic, A Widmark, M Hultdin, A Bergh, S Degerman, P Wikström |
Clinical Epigenetics | 2021 |
|
Charting differentially methylated regions in cancer with Rocker-meth
M Benelli, GM Franceschini, A Magi, D Romagnoli, C Biagioni, I Migliaccio, L Malorni, F Demichelis |
2021 | |
|
Epigenetics in prostate cancer: clinical implications
V Conteduca, J Hess, Y Yamada, SY Ku, H Beltran |
Translational andrology and urology | 2021 |
|
DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder Cancer
F Ye, Y Liang, J Hu, Y Hu, Y Liu, Z Cheng, Y Ou, C Xu, H Jiang |
Frontiers in Cell and Developmental Biology | 2021 |
|
Serine and one-carbon metabolisms bring new therapeutic venues in prostate cancer
C Ganini, I Amelio, R Bertolo, E Candi, A Cappello, C Cipriani, A Mauriello, C Marani, G Melino, M Montanaro, M Natale, G Tisone, Y Shi, Y Wang, P Bove |
2021 | |
|
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis
J Berchuck, S Baca, H McClure, K Korthauer, H Tsai, P Nuzzo, K Kelleher, M He, J Steinharter, S Zacharia, S Spisak, J Seo, V Conteduca, O Elemento, J Auh, M Sigouros, E Corey, M Hirsch, M Taplin, T Choueiri, M Pomerantz, H Beltran, M Freedman |
Clinical cancer research | 2021 |
|
Genomic and phenotypic heterogeneity in prostate cancer
MC Haffner, W Zwart, MP Roudier, LD True, WG Nelson, JI Epstein, AM Marzo, PS Nelson, S Yegnasubramanian |
Nature Reviews Urology | 2020 |
|
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
L Keller, Y Belloum, H Wikman, K Pantel |
British Journal of Cancer | 2020 |
|
Cell-Free DNA-Methylation-Based Methods and Applications in Oncology
F Galardi, FD Luca, D Romagnoli, C Biagioni, E Moretti, L Biganzoli, AD Leo, I Migliaccio, L Malorni, M Benelli |
Biomolecules | 2020 |
|
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
V Conteduca, D Wetterskog, E Scarpi, A Romanel, G Gurioli, A Jayaram, C Lolli, DG Tandefelt, G Schepisi, C Casadei, A Wingate, F Matteucci, G Paganelli, E Gonzalez-Billalabeitia, F Demichelis, UD Giorgi, G Attard |
British Journal of Cancer | 2020 |
|
AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
MD Winther, G Kristensen, HV Stroomberg, KD Berg, BG Toft, JD Brooks, K Brasso, MA Røder |
Diagnostics | 2020 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)